Team members
 

Next-generation therapies in lung cancer

Paul HOFMAN, Professor-Clinician, PU-PHCE
 

Leader

Professor-Clinician, PU-PHCE
Tel: +33 (0)4 92 03 88 55
Dr Paul Hofman is Professor of Pathology at the Nice Sophia Antipolis University, France. He graduated in Nice and in Paris. Then he was a fellow in Pathology at the Brigham and Women’s Hospital (Boston, Harvard Medical School US) from 1993 to 1996. He is PhD in Cell Biology (University of Montpellier, France). He is the head of the Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, University of Nice Sophia Antipolis, France since 2003. He is the director of the “FHU” OncoAge at Nice Sophia Antipolis (www.oncoage.org) and of the Hospital-related Biobank (BB-0033-00025) located in the Comprehensive Cancer Center and in the Hospital of Nice. He is the director of a research unit at the Inserm U 10181/UMR CNRS 7284 (IRCAN center) aiming to decipher the mechanisms occurring during the cross talk between immune cells and cancer cells. IRCAN and OncoAge Centers aim to better understanding the different processes linking ageing process and cancer diseases. He published more than 387 papers.
 

Current members

M.D, Ph.D student
Tel: 0492031245
Ph. D student
Tel: 0492031245
Researcher, CRCN Inserm
Tel: +33 (0)4 92 03 12 43
B Mograbi is aimed at understanding regulatory mechanisms of autophagy, inflammation, and immunosuppression by the scaffold protein SQSTM1 in cancer. She is best known for the discovery that a type of autophagy degrades and maintains the appropriate level of active signaling proteins to achieve tumor suppression (Signalphagy). Her team was also the first to show that low doses of pollutants, close to an environmental exposure, can suppress autophagy; explaining the adverse carcinogenic and inflammatory effects (GENEXPOSOMICS). Her current works focuses both on determining new environment/genetic risk factors predisposing people to lung diseases (COPD, cancers) as well as developing new therapeutic strategies that utilize the patient’s immune system to fight cancer (IMMUNOquest).
Engineer, IECN Inserm
Tel: +33 (0)4 92 03 12 43
IR, CDD CNRS
Tel: 0492031245
PU-PH
Tel: 0492031245
Clinician, MCU-PH
Tel: +33 (0)4 92 03 88 55
Pathologist specialist in melanoma, lung cancer and head and Neck carcinoma. Biobanking.
Researcher, CRCN CNRS
Tel: +33 (0)4 92 03 16 02
Integrative single-cell approaches to understanding cancer drug response heterogeneity in tumor cell dynamics Our ongoing research is aimed at identifying the molecular origins of drug response heterogeneity underlying resistance to anticancer therapies, to ultimately isolate novel druggable targets promoting cell death in resistant tumor cells. Tumor cells of a single clonal population can still exhibit multiple levels of heterogeneity, from gene expression to various drug response behaviors. Drug response variability is one of the immediate causes of drug resistance, contributing to the reduced efficacies of anticancer therapeutics (fractional killing). Using both experimental and computational approaches, including live cell microscopy, dynamic profiling methods and mathematical models of increasing complexity, we search to identify the minimal biological networks of cell death signaling that captures the extent of response heterogeneity giving rise to drug resistance.
MD, PhD student
Tel: +33 (0)4 92 31 22 30
Resident in pneumology, I'm doing my PhD under the supervison of Dr V. Vouret-Craviari. My aims are to characterize the expression of splice variants of P2RX7 in pathologic lung tissues
IR CNRS, non permanent
Tel: 0492031245
Ph. D
Tel: 0492031245
Engineer, Non permanent CNRS
Tel: + 33 (0)4 92 03 12 43
Professor-Clinician, PUPH
Tel: +33 (0)4 92 03 82 63, +33 (0)4 92 02 16 02
Marius Ilié is Professor of Pathology at the Nice Medical School, and Surgical Pathologist at the Clinical and Experimental Pathology Laboratory, Nice University Hospital, Université Côte d’Azur. He has a longstanding interest and expertise in the area of prognostic and predictive biomarkers in thoracic oncology as well as in Biobanking. He has contributed to several publications in the field of biomedical research and biorepository science.
PhD Student
Tel: +33 (0)4 92 03 12 45
Researcher, CRCN Inserm
Tel: +33 (0)4 92 03 12 45
The aim of our research is to identify new mechanisms affecting the metabolism of coding and non-coding RNAs in human pathologies in order to propose new diagnostic, prognostic or predictive biomarkers for treatment response. Our approaches combine cell biology (microscopy, cytometry, ...) and molecular biology (plasmid construction, RNAi, CRISPR / CAS9 ...) and rapid translation to validate our biomarkers on patient biopsies and clinical data.
Clinician, MCU-PH
Tel: +33 (0)4 92 03 16 02
Pathologist specialist in melanoma, lung cancer and head and Neck carcinoma. Biobanking.
PhD student
Tel: +33 (0)4 92 03 12 42
Technician, TCE Inserm
Tel: +33 (0)4 92 03 12 23
Research Director, DR2 CNRS
Tel: +33 (0)4 92 03 12 23
Working on the field of purinergic signaling and diseases, I developed new pharmacologic tools to modulate the activity of the purinergic receptor P2RX7. Our aims are to decipher the role of P2RX7 in the setup of efficient anti-tumor immune responses and to validate the use of our new molecules to enhance anti tumor’s P2RX7 activities.
Clinician, PH
Tel: +33 (0)4 92 03 88 55
Pathologist specialist in melanoma, lung cancer and head and Neck carcinoma. Biobanking.
Ph.D student
Tel: 0492031245
 

Alumni

M.D., Master student
Tel: 0492031245
PU-PH
Tel: 0492031245
ERASMUS
Tel: 0492031245
IE
Tel: 0492031245
Master student
Tel: 0492031245
IE
Tel: 0492031245
Master student
Tel: 0492031243
PhD Student
Tel: + 33 (0)4 92 03 12 45
PU-PH
Tel: 0492031245
Ph.D
Tel: 0492031245
L3 internship
Tel: 0492031245
Researcher, Non permanent CNRS
Tel: +33 (0)4 92 03 12 23
Master student
Tel: 0492031245
Engineer, IR non perment CNRS
Tel: + 33 (0)4 92 03 12 45
PhD Student
Tel: + 33 (0)4 92 03 12 45
My main focus are applied mathemathics and statistics analysis of general problems in biology. At the moment i am finishing a PhD where i am studying the dynamics of the apoptosis signaling pathway and how to sensitize a resistant population of cancer cells and make them more prone to respond to a cancer drug therapy. For that i search for differences in resistant cells versus a cohort of responder cells treated with TRAIL, interpret their heterogeneity, and use a model of ordinary differential equations, based on mass-action-law, to capture their differences.
IE
Tel: 0492031243
Master student
Tel: 0492031245
PhD Student
Tel: +33 (0)4 92 03 12 45
L3 internship
Tel: 0492031245
Master 1 student
Tel: 0492031245
Researcher Non Permanent
Tel: +33 (0)4 92 03 12 23
I did my PhD under the supervision of Dr Vouret-Craviari. I'm now a post doc fellow at Hospital for Special Surgery, New York, USA
BTS internship
Tel: 0492031245
PhD Student
Tel: +33 (0)4 92 03 88 55
Master student
Tel: 0492031245
Master student
Tel: 0492031245
Master student
Tel: 0492031245
M.D., Ph.D
Tel: 0492031245
Research teams